Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1. - Suppr | 超能文献

Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1.

作者信息

Lutz E M, MacKenzie C J, Morrow J, Mitchell R, Bennie J, Carroll S, Clark E, Harmar A J

机构信息

MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh, Scotland.

出版信息

Ann N Y Acad Sci. 1996 Dec 26;805:574-8. doi: 10.1111/j.1749-6632.1996.tb17522.x.

DOI:10.1111/j.1749-6632.1996.tb17522.x

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Chimaeric VIP2/PACAP receptors reveal that agonist pharmacology but not signal transduction is determined by extracellular domain 1.

Ann N Y Acad Sci. 1996 Dec 26;805:574-8. doi: 10.1111/j.1749-6632.1996.tb17522.x.

2

Molecular characterisation of novel receptors for PACAP and VIP.垂体腺苷酸环化酶激活肽和血管活性肠肽新型受体的分子特征

Biochem Soc Trans. 1995 Feb;23(1):83S. doi: 10.1042/bst023083s.

3

Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.血管活性肠肽（VIP）和垂体腺苷酸环化酶激活肽（PACAP）受体在调节大鼠背角神经元对感觉输入反应中的作用证据。

Neuropeptides. 1997 Apr;31(2):175-85. doi: 10.1016/s0143-4179(97)90087-1.

4

Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.垂体腺苷酸环化酶激活多肽（PACAP）和血管活性肠肽（VIP）通过大鼠骨髓来源的基质细胞中PACAP/VIP受体的第三种亚型刺激白细胞介素-6的产生。

Endocrinology. 1997 Jun;138(6):2515-20. doi: 10.1210/endo.138.6.5169.

5

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.长效血管活性肠肽激动剂RO 25 - 1553对VIP2受体亚类具有高度选择性。

Peptides. 1997;18(3):403-8. doi: 10.1016/s0196-9781(96)00322-1.

6

Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.人良性增生前列腺中血管活性肠肽/垂体腺苷酸环化酶激活肽受体的特征分析

Endocrinology. 1996 Jul;137(7):2815-22. doi: 10.1210/endo.137.7.8770902.

7

Phospholipase C activation by VIP1 and VIP2 receptors expressed in COS 7 cells involves a pertussis toxin-sensitive mechanism.

Ann N Y Acad Sci. 1996 Dec 26;805:579-84. doi: 10.1111/j.1749-6632.1996.tb17523.x.

8

PACAP/VIP receptors in pancreatic beta-cells: their roles in insulin secretion.胰腺β细胞中的垂体腺苷酸环化酶激活肽/血管活性肠肽受体：它们在胰岛素分泌中的作用

Ann N Y Acad Sci. 1996 Dec 26;805:44-51; discussion 52-3. doi: 10.1111/j.1749-6632.1996.tb17472.x.

9

Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.垂体腺苷酸环化酶激活多肽/血管活性肠肽受体亚型在垂体克隆生长激素细胞和促性腺激素细胞中的差异表达。

Endocrinology. 1995 May;136(5):2088-98. doi: 10.1210/endo.136.5.7720658.

10

VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.血管活性肠肽1型和2型受体而非垂体腺苷酸环化酶激活肽1型受体介导血管活性肠肽/垂体腺苷酸环化酶激活肽对T淋巴细胞细胞因子产生的作用。

Ann N Y Acad Sci. 1998 Dec 11;865:397-407. doi: 10.1111/j.1749-6632.1998.tb11204.x.

引用本文的文献

1

The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.人血管活性肠肽/垂体腺苷酸环化酶激活肽受体1（VPAC1）启动子：在结肠癌细胞系Caco-2Cl.20肠细胞分化过程中对受体表达的特征及作用

Biochem J. 2000 May 1;347 Pt 3(Pt 3):623-32.

2

Domains determining agonist selectivity in chimaeric VIP2 (VPAC2)/PACAP (PAC1) receptors.决定嵌合型血管活性肠肽2（VPAC2）/垂体腺苷酸环化酶激活肽（PACAP）（PAC1）受体中激动剂选择性的结构域。

Br J Pharmacol. 1999 Oct;128(4):934-40. doi: 10.1038/sj.bjp.0702872.